| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.9 | 2.3 |
| Gross profit | 1.0 | 1.4 |
| Profit before tax | 0.3 | -4.9 |
| Net income | 0.3 | -4.9 |
| EPS (diluted, $ a share) | $0.01 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -18.4% |
|---|---|
| Gross margin | 53.8% |
| Operating margin | -64.3% |
10-Q filed with the SEC, OTC: AWHL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aspira Women's Health Inc.: key numbers
- Share price
- $0.1500Close, Nov 17
- Market cap
- $7M
- Shares outstanding
- 46.63MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aspira Women's Health Inc.
All →Aspira Women's Health Other 8-K Filing
Aspira Women's Health announced that its previously issued financial statements for the first two quarters of 2026 should no longer be relied upon due to material errors in the Statement of Cash Flows. The errors involved the misclassification of loan proceeds and repayments as operating activities instead of financing activities. The company plans to restate these periods, though the adjustments have no impact on the reported balance sheets, statements of operations, or total net change in cash.